These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16303033)

  • 21. Antimicrobial actions of benzimidazoles against oral streptococci.
    Nguyen PT; Baldeck JD; Olsson J; Marquis RE
    Oral Microbiol Immunol; 2005 Apr; 20(2):93-100. PubMed ID: 15720569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: acid-related disease--what are the unmet clinical needs?
    Katz PO; Scheiman JM; Barkun AN
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():9-22. PubMed ID: 16700899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations.
    Devlin JW; Welage LS; Olsen KM
    Ann Pharmacother; 2005 Oct; 39(10):1667-77. PubMed ID: 16118266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
    O'Connell MB; Madden DM; Murray AM; Heaney RP; Kerzner LJ
    Am J Med; 2005 Jul; 118(7):778-81. PubMed ID: 15989913
    [No Abstract]   [Full Text] [Related]  

  • 25. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.
    Olbe L; Carlsson E; Lindberg P
    Nat Rev Drug Discov; 2003 Feb; 2(2):132-9. PubMed ID: 12563304
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
    Zhang W; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: proton pump inhibitors and bacterial overgrowth.
    Williams C; McColl KE
    Aliment Pharmacol Ther; 2006 Jan; 23(1):3-10. PubMed ID: 16393275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
    Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
    J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dexlansoprazole MR.
    Aslam N; Wright R
    Expert Opin Pharmacother; 2009 Oct; 10(14):2329-36. PubMed ID: 19708852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of proton pump inhibitors on vitamins and iron.
    McColl KE
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S5-9. PubMed ID: 19262546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a proton-pump inhibitor for metabolic disturbances associated with anorexia nervosa.
    Eiro M; Katoh T; Watanabe T
    N Engl J Med; 2002 Jan; 346(2):140. PubMed ID: 11784888
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical implications of immediate-release PPI therapy in the management of GERD and upper GI bleeding. Introduction.
    Peura DA
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():1. PubMed ID: 16303030
    [No Abstract]   [Full Text] [Related]  

  • 33. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
    Harewood G
    N Engl J Med; 1999 Oct; 341(18):1398; author reply 1398-9. PubMed ID: 10577093
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
    Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
    Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA
    Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: the clinical pharmacology of proton pump inhibitors.
    Sachs G; Shin JM; Howden CW
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():2-8. PubMed ID: 16700898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of orally administered omeprazole on abomasal luminal pH in dairy calves fed milk replacer.
    Ahmed AF; Constable PD; Misk NA
    J Vet Med A Physiol Pathol Clin Med; 2005 Jun; 52(5):238-43. PubMed ID: 15943608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of proton pump inhibitor calls to Texas poison centers, 1998-2004.
    Forrester MB
    J Toxicol Environ Health A; 2007 Apr; 70(8):705-14. PubMed ID: 17365625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
    Grady H; Murakawa Y; Mulford D; Kukulka M
    J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.